


Pelargonidin protects retinal ganglion cells in a streptozotocin-induced diabetic rat model by reducing intraocular pressure, suppressing TGF- β and activating JAK2/STAT3 signalling pathway

HAICHUN YU¹
ASHRAF ALBRAKATI²
EJAZ AKBAR WANI³
YING LI^{4*} 

¹ Department of
Anesthesiology, Xindu
District, People'
Hospital of Chengdu
Chengdu, 610500, China

² Human Anatomy
Department, College of
Medicine, Taif University
Taif, Saudi Arabia

³ Department of
Ophthalmology
Government Medical
College Srinagar
190010, J&K, India

⁴ Department of
Endocrinology, Xi'an
Trade Union Hospital
Xi'an, 710100, China

License



© 2026 Yu et al.

This article is distributed
under the terms of the
license Creative Commons
Attribution-NonCommercial-
NoDerivatives

4.0 International License

Accepted March 19, 2026
Published online March 20,
2026

ABSTRACT

Diabetic retinopathy (DR) is one of the primary causes of vision impairment, affecting individuals with diabetes, and is marked by the neurodegeneration of the retina along with increased intraocular pressure (IOP). This study sought to determine the effects of pelargonidin on extracellular matrix (ECM) modulation and the inhibition of transforming growth factor- β (TGF- β) and Janus Kinase 2/Signal Transducer and Activator of Transcription 3 (JAK2/STAT3) pathway in retinal ganglion cells of streptozotocin-induced diabetic rats. Male Sprague-Dawley rats (180–200 g) were rendered diabetic by intraperitoneal administration of streptozotocin (STZ). The rats were divided into 5 groups: control, diabetic model (STZ), STZ + low dose pelargonidin (12.5 mg kg⁻¹ per day), STZ + medium dose pelargonidin (25 mg kg⁻¹ per day) and STZ + high dose pelargonidin (50 mg kg⁻¹ per day). IOP was monitored using a tonometer. Whole-mount retinal immunofluorescence staining using RNA-binding protein with multiple splicing (RBPMS) was performed to assess retinal ganglion cell (RGC) density. Protein expression levels of apoptotic markers, ECM components, and TGF- β and JAK2/STAT3 signalling pathways were evaluated by Western blotting. Pelargonidin treatment dose-dependently reduced the elevated IOP. Importantly, immunofluorescence analysis revealed a marked dose-dependent preservation of retinal ganglion cell (RGC) density: STZ-induced RGC loss was significantly reversed by pelargonidin, with the highest dose restoring RGC density to near-control or higher levels in both the central and peripheral retina. This was achieved *via* modulation of apoptosis-related proteins through the upregulation of Bcl-xL, Bcl-2, and downregulation of Bad, Bax and cleaved caspase-3. Furthermore, pelargonidin modulated ECM remodelling protein expression in the RGC layer. In particular, TGF- β 2/Smad2/3 signalling was downregulated, and the JAK2/STAT3 pathway was upregulated. By reducing IOP, preserving RGC density, modulating ECM deposition, inhibiting TGF- β and upregulating the JAK2/STAT3 pathway, pelargonidin exerts protective effects against diabetic retinal injury. The results of this study further confirm the pharmacological potential of pelargonidin as a therapeutic agent for diabetic retinopathy.

Keywords: diabetic retinopathy, pelargonidin, intraocular pressure, retinal ganglion cells, TGF- β

* Correspondence; e-mail: Yinglixtuh01@outlook.com

INTRODUCTION

Worldwide, diabetic retinopathy (DR) is the foremost reason for vision impairment amongst adults of working age, and it poses growing challenges to public health systems (1). Effective treatment and prevention measures are urgently needed to address the risk of diabetes-related sight-threatening visual impairment, which, according to estimates, may grow twofold within the next two and a half decades (2). Traditionally, DR has been viewed as a microvascular disease with a hallmark injury to the retinal microvascular system (3). Known clinical indicators such as microaneurysms, haemorrhages, and new blood vessels have long been associated with the pathogenesis of visual disability in diabetics (4).

Increasing data, however, suggest that DR also involves some degree of neurodegeneration as well (5). It is both interesting and concerning that the loss of RGCs is also a prominent feature of DR – an abnormal condition commonly associated with high IOP (6, 7). Furthermore, an association has been established between diabetes and elevated IOP, indicating that there may be common pathological pathways between DR and glaucoma (8). This investigation seeks to determine whether diabetes has an effect on IOP by assessing diabetic rats in comparison to age-matched controls, with the intention of clarifying how metabolic illness interconnects with damage caused by pressure on the retina.

Among the inventory of experimental models, the STZ-induced diabetic rats are arguably the most frequently used for the study of DR (9). Its early pathological stage can be observed alongside human-like DR features, especially in terms of vascular and neuronal complications (10). While rats are well documented in DR research, there is a gap where rats fulfil various experimental roles (11). Evidence provided by multiple studies supports that diabetic rats indeed suffer from the loss of retinal neurons, making them appropriate subjects for research aimed at neurodegeneration brought about by diabetes (5). Regardless, outcomes from diabetic murine models do not appear to be consistent. Some studies report significant RGC loss, whereas others show no marked neuronal degeneration. Such discrepancies require further research to determine the degree and timing of neurodegeneration in diabetic rats.

Newer studies have noted that the TGF- β signaling pathway is vital for maintaining retinal vasculature and represents a prospective site of intervention for DR (12). TGF- β is crucial for the regulation of vascular homeostasis, including endothelial barrier maintenance and pericyte maturation. Pericyte communication is necessary for vascular integrity, and many of these interactions are facilitated by members of the TGF- β family (13). A breach in this signalling pathway gives rise to retinal pathology mimicking DR. For instance, mice having a conditional TGF- β knockout in retinal tissues form microaneurysms, haemorrhages, and cotton wool spots, which are characteristic of diabetic patients (14). The role that TGF- β plays in the pathogenesis of DR is dualistic. Initially, it seems to offer protective effects by stabilising the vascular system. Yet, chronic or excessive TGF- β activation or dysregulation can lead to pathological features, such as excessive endothelial proliferation, pericyte loss, and fibrosis. Thus, TGF- β dysregulation is increasingly regarded as central to microvascular dysfunctions that accompany diabetes, and as a potential therapeutic target (15). Alongside TGF- β , the Janus kinase/signal transducer activator of transcription 3 (JAK/STAT3) pathway also regulates retinal neuroprotection (16). This pathway is known for its stress response activity, promoting neuronal survival

during heightened IOP. JAK/STAT3 activation has been associated with increased survival of RGCs in optic nerve injury (17).

Also, there is increasing evidence regarding the protective effects of pelargonidin, an anthocyanidin found in berries and other pigmented fruits (18). These compounds serve as potent antioxidants and have been shown to alleviate oxidative damage, ischemic brain injury, and age-associated decline in cognitive functions (19). In this light, we propose that pelargonidin, a bioactive agent with anti-inflammatory and neuroprotective activity, may have the ability to modulate TGF- β 2 and JAK/STAT3 signalling to control IOP elevation.

EXPERIMENTAL

Chemicals and antibodies

Santa Cruz Biotechnology (USA) provided primary antibodies against cleaved caspase-3, TGF- β , TGF- β 2, JAK2, STAT3, p-JAK2, p-STAT3, Bcl-2, Bcl-xL, Bad, β -actin, along with HRP-conjugated IgG secondary antibodies. Cell Signaling Technology (USA) provided antibodies for Smad2, p-Smad2, Smad3, p-Smad3, as well as elastin, fibronectin, collagen types I and IV, laminin, MMP-1, MMP-9, and TIMP1. Pelargonidin (purity $\geq 90\%$ by HPLC) and other reagents and buffer constituents used in expression and biochemical analyses were purchased from Sigma-Aldrich (USA). All other chemicals not mentioned here were of analytical grade.

Experimental animals

The institutional animal facility provided a total of fifty male Sprague Dawley rats (180–200 g). The methodological procedures in this study concerning animal care were approved by the Laboratory Animal Ethics Committee, West China Hospital, Sichuan University (Ethics Approval No. 20241225003) and were carried out in compliance with international guidelines for the care and use of laboratory animals, in accordance with international standards. The rats were housed in sterile polypropylene cages (three animals per cage) under a controlled environment with a 12-hour light/dark cycle, and the temperature was maintained at 22–23 °C, while the relative humidity was set at 55–60 %. The animals were allowed to acclimatise to the laboratory environment for five days prior to the experiment.

Study design

The rats were randomly divided into five experimental groups ($n = 10$ per group). For two consecutive days, intraperitoneal injections of 100 mg kg⁻¹ streptozotocin (STZ, Sigma, USA) were administered. Prior to injection, STZ was dissolved in a sodium citrate buffer (0.1 mol L⁻¹, pH 4.5). Control group rats received an equal amount of sodium citrate buffer without STZ. Intraocular pressure (IOP) was assessed immediately after induction.

Group I (Control) rats received only sodium citrate buffer without STZ for the duration of the five-week experimental period. Group II (Model) rats received STZ injections to induce diabetes and were maintained without further treatment for five weeks. Group III rats received STZ injections followed by oral administration of pelargonidin at a dose of

12.5 mg kg⁻¹ body weight on alternate days for five weeks. Group IV rats received STZ injections followed by oral administration of pelargonidin at a dose of 25 mg kg⁻¹ body weight on alternate days for five weeks. Group V rats received STZ injections followed by oral administration of pelargonidin at a dose of 50 mg kg⁻¹ body weight on alternate days for five weeks.

The doses of pelargonidin (12.5, 25, and 50 mg kg⁻¹) were selected based on previous pharmacological studies demonstrating the safety and biological activity of pelargonidin within this dose range in rodent models (20, 21). These doses were chosen to evaluate a dose-dependent response while remaining within a range reported to exert antioxidant, anti-inflammatory, and neuroprotective effects without producing toxicity.

Measurement of intraocular pressure (IOP)

Procedures for the measurement of IOP were performed while the animals were maintained under inhalation anaesthesia with isoflurane. The IOP was assessed weekly for five weeks using a calibrated TonoLab rebound tonometer (Colonial Medical Supply Co., USA) according to standard methods (22). All measurements were done at the same time each day to eliminate the effects of circadian rhythm changes.

Although isoflurane anaesthesia has been reported to influence ocular physiological parameters, including transient changes in IOP, the same anaesthetic protocol was applied consistently across all experimental groups to minimise variability in the measurements.

Immunofluorescence staining of RGCs in flat-mount retinas

Rats were sacrificed at the end of the treatment period by cervical dislocation, and the eyeballs were immediately enucleated. Six retinas per experimental group were immunostained. Eye globes were fixed in 4 % paraformaldehyde (PFA) in 0.1 mol L⁻¹ PBS (pH 7.4) at room temperature for 2 h, and washed with PBS and kept in 30 % sucrose at 4 °C. The retinas were then isolated, rinsed in PBS, and incubated in blocking/permeabilisation buffer (PBS with 2 % Triton X-100 and 5 % FBS).

To selectively label the retinal ganglion cells, the retinas were incubated with RBPMS primary antibody (Phosphosolutions #1832; 1:500) for 48 h at 4 °C. Following PBS washes, tissues were incubated with Alexa Fluor 488 goat anti-rabbit secondary antibody (1:200, Invitrogen) for 48 h at 4 °C. Again, retinas were washed and flat-mounted on glass slides, and coverslipped with DAPI-containing mounting medium (Vector Labs H-1200).

Images were obtained using a standard fluorescence microscope. Four radial and opposite fields were recorded on each retina in the central part (around 500 μ m from the optic nerve head) and the peripheral part (around 500 μ m from the retinal edge). ImageJ was used to process all the images. The RGC density was computed as the number of RBPMS⁺ cells per scanned field. For quantification, images were analysed using ImageJ software (NIH, USA) under identical acquisition and threshold settings for all groups. RBPMS⁺ cells were manually counted within defined fields of equal area, and cell counts were converted to RGC density (cells/mm²). All analyses were performed in a blinded manner to minimise observer bias.

Western blot analysis

The levels of expressed proteins in retinal tissues were assessed by Western blotting. RIPA buffer that was supplemented with a protease inhibitor cocktail (Sigma-Aldrich) was used to lyse tissues, and total protein concentrations were determined by a BCA protein assay kit (Thermo Fisher Scientific, USA). Equal amounts of protein (60 μg) were separated by 10–12 % SDS-PAGE, and the proteins were subsequently transferred to PVDF membranes (Invitrogen). Membranes were blocked with 5 % non-fat dry milk in TBST (137 mmol L⁻¹ NaCl, 20 mmol L⁻¹ Tris, 0.1 % Tween-20, pH 7.6) for 1 h at 37 °C and then incubated with primary antibodies at a dilution of 1:1000 overnight at 4 °C. Afterward, membranes were washed and incubated with HRP-conjugated secondary antibodies (1:2000 dilution) at 37 °C for 1 h. Enhanced chemiluminescence (Millipore, USA) was used for Western blotting detection, and images acquired from the ChemiDoc XRS system (Bio-Rad, USA) were analysed.

For each experimental group, retinal protein extracts from independent animals ($n = 10$ per group) were used as biological replicates, and Western blot analysis was performed in triplicate to ensure reproducibility. Band intensities were quantified using ImageJ software, and the expression levels of target proteins were normalised to β -actin, which served as the internal loading control. The normalised values were then expressed relative to the control group, and data were presented as mean \pm SEM to account for biological variability.

Statistical analysis

SPSS version 21.0 (SPSS Inc., USA) was the tool utilised for statistical analysis. One-way ANOVA was performed to assess the differences among groups, followed by Duncan's Multiple Range Test (DMRT) post hoc analysis. A threshold of $p < 0.05$ was used to define statistical significance.

RESULTS AND DISCUSSION

Pelargonidin significantly reduces intraocular pressure in diabetes induced rats

Diabetes induced by STZ resulted in a sustained and progressive rise in the IOP of rats over the 5-week experimental period (Fig. 1). The baseline values of IOP were similar in all the groups (16.5–17.8 mmHg). Nevertheless, IOP showed a marked increase in the diabetic model group (Group II) beginning at Week 1, and continued to rise over time. Week 3 showed an increase in IOP beyond baseline (~34–35 mmHg), and this further increased to about 38 mmHg in Weeks 4 and 5, indicating the successful development of diabetes-related ocular hypertension. Pelargonidin systemic administration significantly inhibited the STZ-induced increase in IOP in a dose-dependent manner. Group III (12.5 mg kg⁻¹) recorded a moderate decrease in IOP with the values of 28–31 mmHg in Week 3, 29–30 mmHg in Week 4 and 26–28 mmHg in Week 5. In Group IV (25 mg kg⁻¹), a more significant drop was observed, and IOP reached about 26–29 mmHg during Week 3, 26–27 mmHg during Week 4 and approached near-normal levels (approximately 22–23 mmHg) during Week 5. The greatest effect was observed at the highest dose (50 mg kg⁻¹, Group V), where




Fig. 1. Pelargonidin treatment reduces IOP in STZ-induced diabetic rats. IOP was determined over a period of 5 weeks. Pelargonidin significantly reduced IOP in STZ-induced diabetic rats in a dose-dependent manner. Groups: I (Control), II (STZ), III (STZ + pelargonidin 12.5 mg kg⁻¹), IV (STZ + pelargonidin 25 mg kg⁻¹) and V (STZ + pelargonidin 50 mg kg⁻¹). Data are expressed as mean \pm SEM ($n = 10$ rats per group). * $p < 0.05$ vs. control; # $p < 0.05$ vs. STZ control.

IOP values decreased to 24–26 mmHg at Week 3, 21–23 mmHg at Week 4, and 17–19 mmHg at Week 5, which were similar to the control levels.

Diabetic retinopathy is an advanced neurovascular consequence of diabetes and is still one of the most important causes of irreversible loss of sight globally (23). There is an ongoing concept of nerve cell damage taking place at an early stage, including RGC degeneration prior to significant microvascular insults developing (24). It is in this light that we documented the action of pelargonidin, a natural anthocyanidin, in a streptozotocin-induced diabetic rat model.

An important finding from the current study is that pelargonidin is able to significantly reduce IOP in diabetic rats. Increased IOP is not only a feature of glaucoma, but has also been increasingly noted in diabetic states, thereby adding to the stress and degeneration of RGCs (25). Restoring IOP is consistent with previous research reporting ocular hypotension induced by flavonoids and proposes that pelargonidin can mitigate the impact of RGC damage in diabetic retinopathy, potentially *via* alteration of aqueous humour circulation or trabecular meshwork homeostasis (26).

Pelargonidin effect on RGC density

Retinal immunofluorescence staining of whole-mount retina with an RGC-specific marker, RBPMS, showed that the distribution of RGCs among the five experimental groups differed significantly (Fig. 2). Group I rats (control group) exhibited a homogenous high cell density in both the central and peripheral parts of the retina, indicating normal retinal architecture. Conversely, the retinal density of RGCs in Group II diabetic rats (STZ-induced)

showed a significant reduction throughout the retina, indicating diabetes-induced neurodegeneration, with greater loss in the peripheral region. Pelargonidin treatment resulted in dose-dependent preservation of RGC density. Group III (12.5 mg kg⁻¹) showed a slight but significant improvement in the density of RGCs relative to the diabetic group, indicating partial neuroprotection. The Group IV (25 mg kg⁻¹) showed a more pronounced recovery of RGC density in both central and peripheral retina, restoring a significant proportion of lost cells. Interestingly, Group V (50 mg kg⁻¹) had comparable or higher RGC densities in both regions compared to the control group, indicating a strong protective effect.

Diabetic retinopathy is marked by apoptosis of RGCs, which contributes significantly to the emergence of neurodegenerative alterations. The pronounced reduction in RGC density in the diabetic condition demonstrates the vulnerability of these neurons to the effects of hyperglycemia-induced oxidative stress and inflammatory damage. The dose-dependent preservation of RGCs following treatment with pelargonidin indicates its strong neuroprotective effect. This protective effect can be attributed to its antioxidant and anti-inflammatory properties, which minimise retinal damage and preserve neuronal




Fig. 2. Flat-mount retina staining of RGC: a) representative images of RBPMS⁺ RGCs in whole-mount retinas from the five experimental groups, I (Control), II (STZ), III (STZ + pelargonidin 12.5 mg kg⁻¹), IV (STZ + pelargonidin 25 mg kg⁻¹) and V (STZ + pelargonidin 50 mg kg⁻¹). STZ-induced diabetes caused a significant decrease in RGC density, whereas pelargonidin treatment preserved RGCs in a dose-dependent manner; b) RGC density was quantified in the central and peripheral retina. Data are expressed as mean \pm SEM ($n = 10$ rats per group). * $p < 0.05$ vs. control; # $p < 0.05$ vs. STZ control.

survival. The considerable restoration of RGC density with increasing doses of pelargonidin further suggests that it can reverse diabetes-induced retinal neurodegenerative changes and preserve retinal integrity.

Pelargonidin alters apoptosis by modulating cleaved caspase-3 and Bcl-2 family protein expression

Western blot analysis showed that STZ-induced diabetes resulted in a significant increase in apoptotic signalling in the retina (Fig. 3). Particularly, the cleaved caspase-3




Fig. 3. Influence of pelargonidin on cleaved caspase-3 and other apoptosis-related proteins: a) representative immunoblots showing cleaved caspase 3 and other apoptosis-related proteins. Lane I (Control), Lane II (STZ), Lane III (STZ + pelargonidin 12.5 mg kg⁻¹), Lane IV (STZ + pelargonidin 25 mg kg⁻¹) and Lane V (STZ + pelargonidin 50 mg kg⁻¹); b) densitometry analysis of the target proteins. Data are expressed as mean \pm SEM ($n = 10$ rats per group). * $p < 0.05$ vs. control; # $p < 0.05$ vs. STZ control.

expression was significantly increased, indicating enhanced apoptosis. Simultaneously, pro-apoptotic proteins Bax and Bad were greatly increased, whereas anti-apoptotic proteins Bcl-2 and Bcl-xL were greatly reduced in the diabetic group, as compared to the control. These changes were reversed successfully using a dose-dependent pelargonidin treatment. Pelargonidin administration reduced cleaved caspase-3, Bax, and Bad and increased Bcl-2 and Bcl-xL expression in all groups of treatment. The strongest effect was shown in the highest dose (50 mg kg⁻¹), where the level of expression of the apoptotic proteins returned close to that of the control group.

The apoptosis of RGCs is one of the major pathological changes observed in DR, which is also associated with oxidative stress, inflammation, and deficiency of neurotrophic factors (27). The observed alterations in apoptotic markers suggest activation of the mitochondrial apoptotic pathway in the diabetic retina, characterised by an imbalance between pro-apoptotic and anti-apoptotic Bcl-2 family proteins. The ability of pelargonidin to restore this balance indicates its protective role against diabetes-induced retinal damage. By enhancing anti-apoptotic signalling and suppressing pro-apoptotic mediators, pelargonidin may help preserve RGC integrity under stress conditions. These findings suggest that pelargonidin exerts its neuroprotective effects, at least in part, through modulation of mitochondrial apoptosis pathways and regulation of caspase-3 activity.

Pelargonidin suppresses TGF- β 2/p-Smad2/3 signalling pathway

A Western blot analysis revealed that STZ-induced diabetes significantly activated the TGF- β 2/Smad signalling pathway in retinal tissue (Fig. 4). TGF- β 2 expression was significantly increased, and phosphorylation of Smad2 and Smad3 was also increased, indicating activation of the canonical fibrotic signalling pathway. It is worth noting that the overall expression levels of Smad2 and Smad3 did not differ among groups. This pathway was suppressed by pelargonidin treatment in a dose-dependent manner. Pelargonidin administration produced a high degree of downregulation of TGF- β 2 expression and decreased the phosphorylation of Smad2 and Smad3. The total Smad 2/3 was found to be close to normal, especially at the highest dose (50 mg kg⁻¹), which implies that it effectively inhibited fibrotic signalling through TGF- β 2.

TGF- β pathway is a central signalling cascade involved in retinal remodeling in diabetes and DR and it could lead to hypertensive complications (28). These conditions can lead to TGF- β 2-induced fibrosis that increases ECM protein deposition through the activation of canonical Smad2/3 signalling. Such mechanisms may be aggravated by cellular stress and were observed in our study. In diabetic rats, we noted a remarkable increase in TGF- β 2 along with p-Smad2 and p-Smad3, indicating activation of the fibrotic signalling pathway. Treatment with pelargonidin resulted in a marked reduction in Smad2/3 phosphorylation along with a significant dose-dependent downregulation in TGF- β 2 expression. This indicates that pelargonidin may attenuate the TGF- β signalling pathway, which otherwise contributes to pathological ECM remodelling in diabetic retinal tissue. As much as there is an association of inflammation with STAT3, its identification in neuronal tissues during diabetic stress has drawn attention as a compensatory survival response. Hence, for our intention, the results showing that pelargonidin augments the said pathway without worsening the state of the inflammatory cytokines – at least – indicate a shift towards neuroprotective STAT3 signalling rather than a pro-inflammatory one. Indeed, this aligns




Fig. 4. Impact of pelargonidin on the TGF- β 2/Smad signalling pathway: a) representative immunoblots showing proteins associated with the TGF- β 2/Smad signalling pathway. Lane I (Control), Lane II (STZ), Lane III (STZ + pelargonidin 12.5 mg kg⁻¹), Lane IV (STZ + pelargonidin 25 mg kg⁻¹) and Lane V (STZ + pelargonidin 50 mg kg⁻¹); b) and c) densitometry analysis of the target proteins. Data are expressed as mean \pm SEM ($n = 10$ rats per group). * $p < 0.05$ vs. control; # $p < 0.05$ vs. STZ control.

with the growing view of context-dependent STAT3 activation, underscoring the complexities of treating retinal pathologies.

Pelargonidin inhibits ECM remodelling in retinal tissue

The ECM profiling showed that there was a major remodelling of the retinal tissue in STZ-induced diabetic rats compared to the control group. Namely, the levels of collagen I, fibronectin, and elastin were significantly higher than in the control group, which suggests increased deposition of the extracellular matrix and fibrosis-associated proteins (Fig. 5). Treatment with pelargonidin greatly suppressed these changes in a dose-dependent manner. The collagen I, fibronectin, and elastin expression were progressively reduced across the treatment groups, with the most significant decrease observed at the highest dose (50 mg kg⁻¹), and they were nearly restored to control levels.

TGF- β signalling not only leads to structural alterations of the ECM, but also actively suppresses debris-clearing neuroprotective activity. To support this, our ECM profiling showed obvious remodelling in the retinal tissue of diabetic rats, which was marked by




Fig. 5. Effect of pelargonidin on the expression of ECM proteins in retinal tissue: a) representative immunoblots showing collagen I, fibronectin, and elastin proteins. Lane I (Control), Lane II (STZ), Lane III (STZ + pelargonidin 12.5 mg kg⁻¹), Lane IV (STZ + pelargonidin 25 mg kg⁻¹), and Lane V (STZ + pelargonidin 50 mg kg⁻¹); b) densitometry analysis of the target proteins. Data are expressed as mean \pm SEM ($n = 10$ rats per group). * $p < 0.05$ vs. control; # $p < 0.05$ vs. STZ control.

increased expression of collagen I, fibronectin, and elastin. Pelargonidin treatment markedly reduced the expression of these ECM markers, particularly at higher doses.

Pelargonidin activates phosphorylation of JAK2/STAT3 signalling pathway

The analysis of protein expression indicated that, under STZ-induced diabetes, the level of phosphorylation of JAK2 and STAT3 was significantly reduced compared to the control group, but the total protein levels of JAK2 and STAT3 changed minimally (Fig. 6). This signifies inhibition of JAK2/STAT3 signalling activity in diabetic conditions. The activation of this pathway was depended on the pelargonidin treatment dose. In particular, the phosphorylation of JAK2 and STAT3 (p-JAK2 and p-STAT3) was significantly enhanced




Fig. 6. Impact of pelargonidin on JAK2/STAT3 signalling pathway: a) representative immunoblots showing proteins associated with the JAK2/STAT3 signalling pathway. Lane I (Control), Lane II (STZ), Lane III (STZ + pelargonidin 12.5 mg kg⁻¹), Lane IV (STZ + pelargonidin 25 mg kg⁻¹), and Lane V (STZ + pelargonidin 50 mg kg⁻¹); b) and c) densitometry analysis of the target proteins. Data are expressed as mean \pm SEM ($n = 10$ rats per group). * $p < 0.05$ vs. control; # $p < 0.05$ vs. STZ control.

after the administration of pelargonidin, and the overall protein concentration was not dramatically altered. The highest dose (50 mg kg⁻¹) had the strongest activation implying the restoration of JAK2/STAT3 signalling under diabetic stress conditions.

The most interesting element of our study is the dual regulation of the JAK2/STAT3 signalling pathway. In circumstances of diabetes-related stress, this pathway tends to mediate both pro-inflammatory and neuroprotective responses, depending on the context of activation as well as the cellular microenvironment (29). In our study, pelargonidin increased the phosphorylation of JAK2 and STAT3 in STZ-induced diabetic rats, while the total protein levels of these proteins were unchanged, as they were already present. As it is widely accepted, activation of STAT3 can lead to increased cell survival, which supports our data on apoptosis and strengthens the statement that pelargonidin augments intrinsic neuroprotection in RGCs through JAK2/STAT3 signalling.

However, it should be noted that the present analysis was performed using whole retinal tissue and therefore does not provide cell-type-specific information. Considering the well-documented dual role of STAT3 signalling in both neuronal survival and inflammatory responses in glial and immune cells, the precise cellular source of JAK2/STAT3 activation cannot be definitively determined in this study. Thus, the interpretation of STAT3 activation as primarily neuroprotective should be considered with caution, and future studies employing cell-type-specific approaches will be required to clarify the underlying mechanisms.

Study limitations

Despite the promising findings, several limitations of the present study should be acknowledged. First, the experiments were conducted in an STZ-induced diabetic rat model, and therefore, the results may not fully reflect the complexity of human diabetic retinopathy. Second, the molecular analyses were performed using whole retinal tissue, which does not allow identification of the specific retinal cell types responsible for the observed signalling changes. Third, although the study demonstrates neuroprotective and anti-fibrotic effects of pelargonidin, pharmacokinetic properties, long-term safety, and optimal dosing were not investigated. Therefore, while our results suggest a potential protective role of pelargonidin in diabetic retinal injury, these findings should be interpreted cautiously and require further validation in additional experimental models and well-designed clinical studies before considering therapeutic application in humans.

CONCLUSIONS

To summarise, we show that pelargonidin provides significant neuroprotection in a streptozotocin-induced diabetic model by reducing IOP, fibrosis, and apoptosis, and by enhancing survival pathways. Importantly, pelargonidin preserved retinal ganglion cell (RGC) density in a clear dose-dependent manner, with the highest dose restoring RGC levels close to normal. These findings suggest that pelargonidin may represent a promising candidate for further investigation as a potential therapeutic strategy for diabetic retinopathy. However, additional studies, including further preclinical validation and clinical evaluation, are required to confirm its therapeutic applicability.

Acknowledgements. – This research was funded by Taif University, Saudi Arabia, under project number TU-DSPP-2024-55. The authors would like to acknowledge the Deanship of Graduate Studies and Scientific Research at Taif University for funding this work.

Conflict of interest. – The authors declare that they have no known conflicts of interest.

Author's contribution. – Conceptualisation, Y.L. and A.A.; investigation, H.Y. and Y.L.; writing, original draft preparation, A.A.; writing, review and editing, E.A.W.; funding acquisition, A.A. All authors have read and approved the final version of the manuscript.

REFERENCES

1. M. Kropp, O. Golubnitschaja, A. Mazurakova, L. Koklesova, N. Sargheini, T. K. S. Vo, E. de Clerck, J. Polivka Jr., P. Potuznik, J. Polivka, I. Stetkarova, P. Kubatka and G. Thumann, Diabetic retinopathy as the leading cause of blindness and early predictor of cascading complications – risks and mitigation, *EPMA J.* 14(1) (2023) 21–42; <https://doi.org/10.1007/s13167-023-00314-8>
2. M. J. Burton, J. Ramke, A. P. Marques, R. R. A. Bourne, N. Congdon, I. Jones, B. A. M. Ah Tong, S. Arunga, D. Bachani, C. Bascaran, A. Bastawrous, K. Blanchet, T. Braithwaite, J. C. Buchan, J. Cairns, A. Cama, M. Chagunda, C. Chuluunkhuu, A. Cooper, J. Crofts-Lawrence, W. H. Dean, A. K. Denniston, J. R. Ehrlich, P. M. Emerson, J. R. Evans, K. D. Frick, D. S. Friedman, J. M. Furtado, M. M. Gichangi, S. Gichuhi, S. S. Gilbert, R. Gurung, E. Habtamu, P. Holland, J. B. Jonas, P. A. Keane, L. Keay, R. C. Khanna, P. T. Khaw, H. Kuper, F. Kyari, V. C. Lansingh, I. Mactaggart, M. M. Mafwiri, W. Mathenge, I. McCormick, P. Morjaria, L. Mowatt, D. Muirhead, G. V. S. Murthy, N.

- Mwangi, D. B. Patel, T. Peto, B. M. Qureshi, S. R. Salomao, V. Sarah, B. R. Shilio, A. W. Solomon, B. K. Swenor, H. R. Taylor, N. Wang, A. Webson, S. K. West, T. Y. Wong, R. Wormald, S. Yasmin, M. Yusufu, J. C. Silva, S. Resnikoff, T. Ravilla, C. E. Gilbert, A. Foster and H. B. Faal, The Lancet Global Health Commission on Global Eye Health: Vision beyond 2020, *Lancet Glob. Health* **9**(4) (2021) e489–e551; [https://doi.org/10.1016/S2214-109X\(20\)30488-5](https://doi.org/10.1016/S2214-109X(20)30488-5)
3. R. Rajagopal and T. Kern, Clinical evidence of a photoreceptor origin in diabetic retinal disease, *Ophthalmol. Sci.* **5**(1) (2025) Article ID 100591 (8 pages); <https://doi.org/10.1016/j.xops.2024.100591>
 4. M. Seewoodhary, An overview of diabetic retinopathy and other ocular complications of diabetes mellitus, *Nurs. Stand.* **36**(7) (2021) 71–76; <https://doi.org/10.7748/ns.2021.e11766>
 5. M. M. Sachdeva, Retinal neurodegeneration in diabetes: An emerging concept in diabetic retinopathy, *Curr. Diab. Rep.* **21**(12) (2021) Article ID 65 (8 pages); <https://doi.org/10.1007/s11892-021-01428-x>
 6. S. Vernazza, F. Oddone, S. Tirendi and A. M. Bassi, Risk factors for retinal ganglion cell distress in glaucoma and neuroprotective potential intervention, *Int. J. Mol. Sci.* **22**(15) (2021) Article ID 8034 (18 pages); <https://doi.org/10.3390/ijms22158034>
 7. M. C. Potilinski, V. Lorenc, S. Perisset and J. E. Gallo, Mechanisms behind retinal ganglion cell loss in diabetes and therapeutic approach, *Int. J. Mol. Sci.* **21**(7) (2020) Article ID 2355 (23 pages); <https://doi.org/10.3390/ijms21072351>
 8. Y. Li, W. Mitchell, T. Elze and N. Zebardast, Association between diabetes, diabetic retinopathy, and glaucoma, *Curr. Diab. Rep.* **21**(10) (2021) Article ID 38; <https://doi.org/10.1007/s11892-021-01404-5>
 9. A. Ghasemi and S. Jeddi, Streptozotocin as a tool for induction of rat models of diabetes: A practical guide, *EXCLI J.* **22** (2023) 274–294; <https://doi.org/10.17179/excli2022-5639>
 10. M. Z. Sadikan, N. A. Abdul Nasir, L. Lambuk, R. Mohamud, N. H. Reshidan, E. Low, S. A. Singar, A. S. Mohamad Sabere, I. Iezhitsa and R. Agarwal, Diabetic retinopathy: A comprehensive update on in vivo, in vitro and ex vivo experimental models, *BMC Ophthalmol.* **23**(1) (2023) Article ID 421 (14 pages); <https://doi.org/10.1186/s12886-023-03155-1>
 11. K. Polewik, M. Kosek, D. Jamrozik, I. Matuszek, A. Smedowski, J. Lewin-Kowalik and M. Pietrucha-Dutczak, Rodent models of diabetic retinopathy as a useful research tool to study neurovascular cross-talk, *Biology* **12**(2) (2023) Article ID 262 (24 pages); <https://doi.org/10.3390/biology12020262>
 12. S. Hachana and B. Larrivee, TGF- β superfamily signaling in the eye: implications for ocular pathologies, *Cells* **11**(15) (2022) Article ID 2336 (29 pages); <https://doi.org/10.3390/cells11152336>
 13. H. Huang, Pericyte-endothelial interactions in the retinal microvasculature, *Int. J. Mol. Sci.* **21**(19) (2020) Article ID 7413 (18 pages); <https://doi.org/10.3390/ijms21197413>
 14. B. M. Braunger, S. V. Leimbeck, A. Schlecht, C. Volz, H. Jagle and E. R. Tamm, Deletion of ocular transforming growth factor beta signaling mimics essential characteristics of diabetic retinopathy, *Am. J. Pathol.* **185**(6) (2015) 1749–1768; <https://doi.org/10.1016/j.ajpath.2015.02.008>
 15. Y. Li, Y. Liu, S. Liu, M. Gao, W. Wang, K. Chen and L. Huang, Diabetic vascular diseases: Molecular mechanisms and therapeutic strategies, *Signal Transduct. Target. Ther.* **8**(1) (2023) Article ID 152 (29 pages); <https://doi.org/10.1038/s41392-023-01400-z>
 16. J. Ren, J. Jiang, W. Ou, X. Luo, J. Xiang, G. Liu, S. Huang, L. He, J. Gan, H. Li and C. Nie, The effect of STAT3 signal pathway activation on retinopathy of prematurity, *Front. Pediatr.* **9** (2021) Article ID 638432 (6 pages); <https://doi.org/10.3389/fped.2021.638432>
 17. S. Chen, K. L. Lathrop, T. Kuwajima and J. M. Gross, Retinal ganglion cell survival after severe optic nerve injury is modulated by crosstalk between Jak/Stat signaling and innate immune responses in the zebrafish retina, *Development* **149**(8) (2022) Article ID dev199694 (10 pages); <https://doi.org/10.1242/dev.199694>

18. N. Alisavari, S. Soleimani-Asl, M. Zarei, N. Hashemi-Firouzi and S. Shahidi, Protective effect of chronic administration of pelargonidin on neuronal apoptosis and memory process in amyloid- β -treated rats, *Avicenna J. Phytomed.* **11(4)** (2021) 407–416; <https://doi.org/10.22038/ajp.2021.56244.2019>
19. L. Kooshki, S. Fakhri, F. Abbaszadeh, A. Kiani, M. H. Farzaei, E. Mohammadi-Noori and J. Echeverria, Pelargonidin improves functional recovery and attenuates neuropathic pain following spinal cord injury in rats: Relevance to its neuroprotective, antioxidant, and anti-inflammatory effects, *Front. Pharmacol.* **16** (2025) Article ID 1547187 (11 pages); <https://doi.org/10.3389/fphar.2025.1547187>
20. M. Mirshekar, M. Roghani, M. Khalili, T. Baluchnejadmojarad and S. Arab Moazzen, Chronic oral pelargonidin alleviates streptozotocin-induced diabetic neuropathic hyperalgesia in rats: Involvement of oxidative stress, *Iran. Biomed. J.* **14** (2010) 33–39.
21. K. Fu, M. Chen, H. Zheng, C. Li, F. Yang and Q. Niu, Pelargonidin ameliorates MCAO-induced cerebral ischemia/reperfusion injury in rats by action on the Nrf2/HO-1 pathway, *Transl. Neurosci.* **12** (2021) 20–31; <https://doi.org/10.1515/tnsci-2021-0006>
22. J. C. Morrison, L. Jia, W. Cepurna, Y. Guo and E. Johnson, Reliability and sensitivity of the Tono-Lab rebound tonometer in awake Brown Norway rats, *Investig. Ophthalmol. Vis. Sci.* **50(6)** (2009) 2802–2808; <https://doi.org/10.1167/iovs.08-2699>
23. Z. Wang, N. Zhang, P. Lin, Y. Xing and N. Yang, Recent advances in the treatment and delivery system of diabetic retinopathy, *Front. Endocrinol.* **15** (2024) Article ID 1347864 (17 pages); <https://doi.org/10.3389/fendo.2024.1347864>
24. J. R. Soucy, E. A. Aguzzi, J. Cho, M. J. Gilhooley, C. Keuthan, Z. Luo, A. Monavarfeshani, M. A. Saleem, X. W. Wang, J. Wohlschlegel, P. Baranov, A. Di Polo, B. Fortune, K. K. Gokoffski, J. L. Goldberg, W. Guido, A. L. Kolodkin, C. A. Mason, Y. Ou, T. A. Reh, A. G. Ross, B. C. Samuels, D. Welsbie, D. J. Zack and T. V. Johnson, Retinal ganglion cell repopulation for vision restoration in optic neuropathy: A roadmap from the RReSTORE consortium, *Mol. Neurodegener.* **18(1)** (2023) Article ID 64 (46 pages); <https://doi.org/10.1186/s13024-023-00655-y>
25. R. Amato, F. Lazzara, T. H. Chou, G. L. Romano, M. Cammalleri, M. Dal Monte, G. Casini and V. Porciatti, Diabetes exacerbates intraocular pressure-independent retinal ganglion cell degeneration in the DBA/2J model of glaucoma, *Investig. Ophthalmol. Vis. Sci.* **62(9)** (2021) Article ID 9 (10 pages); <https://doi.org/10.1167/iovs.62.9.9>
26. P. Maher and A. Hanneken, Flavonoids protect retinal ganglion cells from oxidative stress-induced death, *Investig. Ophthalmol. Vis. Sci.* **46(12)** (2005) 4796–4803; <https://doi.org/10.1167/iovs.05-0536>
27. E. Y. Kang, P. K. Liu, Y. T. Wen, P. M. J. Quinn, S. R. Levi, N. K. Wang and R. K. Tsai, Role of oxidative stress in ocular diseases associated with retinal ganglion cell degeneration, *Antioxidants* **10(12)** (2021) Article ID 1948 (25 pages); <https://doi.org/10.3390/antiox10121948>
28. A. Callan, S. Jha, L. Valdez, L. Baldado and A. Tsin, TGF- β signaling pathways in the development of diabetic retinopathy, *Int. J. Mol. Sci.* **25(5)** (2024) Article ID 3052 (13 pages); <https://doi.org/10.3390/ijms25053052>
29. M. Yang, M. Tian, X. Zhang, J. Xu, B. Yang, J. Yu, F. Li, Y. Li, S. Li and X. Li, Role of the JAK2/STAT3 signaling pathway in the pathogenesis of type 2 diabetes mellitus with macrovascular complications, *Oncotarget* **8(57)** (2017) 96958–96969; <https://doi.org/10.18632/oncotarget.18555>